Driving Progress Against Childhood Cancer
Childhood cancer is rare, yet about 11,050 children in the United States under the age of 15 will be diagnosed with cancer in 2020. While many types of cancers can appear in people of all ages, we know that kids are not just little adults and treatment often needs to be different. Pediatric clinical trials allow for the development of medicines with the unique needs of children in mind and have helped drive great strides against childhood cancer (1). Yet, there is still much more to learn and new advancements to be made.
Currently Lilly is working on an innovative approach to support advancing pediatric research by using master protocols to study new treatments for cancer patients. Master protocols are a novel way to study multiple research questions about several different drugs, diseases or conditions all in one clinical trial (instead of having to have multiple clinical trials) (2). Some of the potential benefits of this approach are to help to quickly test and answer scientific questions, compare different treatment options, reduce the cost of the study, reduce the time to set up new studies or enroll patients to aid in our ability to create medicines for our pediatric cancer patient population faster than we normally would under a non-master protocol clinical trial.
An example of some of our master protocol clinical trials in pediatrics can be found at LillyTrialGuide.com with the heading in the title of the study "CAMPFIRE." CAMPFIRE stands for "Children’s and Young Adult Master Protocol for Innovative Pediatric Research." CAMPFIRE is a platform to accelerate the development of novel treatments for pediatric and young adult patients with cancer. This platform uses innovative designs and an overarching infrastructure to harness the benefits of shared data and operational efficiencies. The investigational agents on the trial will change over time based on the criteria established in the sub-protocols.
Explore the infographic below to learn more about the landscape of childhood cancer and the role of pediatric research in powering progress.
- J. Woodcock, L.M. LaVange. Master protocols to study multiple therapies, multiple diseases, or both. N. Engl. J. Med., 377 (2017), pp. 62-70
Blog post originally appeared on LillyPad.